Organovo Logo (2 Color Med-Res-082117).png
Organovo to Present Clinical Data of FXR314 in Phase 2 MASH in an Oral Presentation at The Liver Meeting Sponsored by the American Association for the Study of Liver Diseases
13 nov. 2024 08h06 HE | Organovo, Inc.
SAN DIEGO, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (Nasdaq:ONVO), a clinical stage biotechnology company focused on developing novel treatment approaches in inflammatory bowel...
3D Bioprinting Market, by Geography
3D Bioprinting Market Industry Trends and Global Forecasts, 2019, 2024 and 2035: Advancements in Biomaterials and AI Integration, & Partnerships and Collaborations Propel the $4 Billion Market
23 oct. 2024 04h02 HE | Research and Markets
Dublin, Oct. 23, 2024 (GLOBE NEWSWIRE) -- The "3D Bioprinting Market Industry Trends and Global Forecasts to 2035: Distribution by Type of Component, Type of Consumable, Type of Technology, Type of...
Exactitude_Consultancy_Logo.png
3D Bioprinting Market valued at USD 1.41 billion in 2024 | ExactitudeConsultancy
16 sept. 2024 03h47 HE | Exactitude Consultancy
Luton, Bedfordshire, United Kingdom, Sept. 16, 2024 (GLOBE NEWSWIRE) -- Exactitude Consultancy, the market research and consulting wing of Ameliorate Digital Consultancy Private Limited has...
22157.jpg
Wound Skin Substitutes Market Global Analysis to 2030, Featuring Coloplast, Smith & Nephew, MTF Biologics, MiMedx, AlloSource, Organogenesis, RTI Surgical, LifeNet Health and Molecular Biologicals
10 juin 2024 06h55 HE | Research and Markets
Dublin, June 10, 2024 (GLOBE NEWSWIRE) -- The "Wound Skin Substitutes Market - A Global and Regional Analysis: Focus on Region, Country-Level Analysis, and Competitive Landscape - Analysis and...
MnM_logo_TM_JPG.JPG
3D Bioprinting Market is Expected to Reach $2.4 billion | MarketsandMarkets™
04 juin 2024 08h30 HE | MarketsandMarkets Research Pvt. Ltd.
Chicago, June 04, 2024 (GLOBE NEWSWIRE) -- 3D Bioprinting market in terms of revenue was estimated to be worth $1.3 billion in 2024 and is poised to reach $2.4 billion by 2029, growing at a CAGR of...
22157.jpg
3D Bioprinting Market Global Forecast to 2030, Featuring EnvisionTEC, Organovo, Inventia Life Science, Poietis, Vivax Bio, Allevi, Cyfuse Biomedical, 3D Bioprinting Solutions & Cellink Global
30 janv. 2024 10h07 HE | Research and Markets
Dublin, Jan. 30, 2024 (GLOBE NEWSWIRE) -- The "3D Bioprinting Market by Component, Material, Application, End User, Regional Outlook - Global Forecast up to 2030" report has been added to ...
22157.jpg
3D-Printed Organs Market Projected to Reach USD 2.13 Billion by 2030 – New Research Highlights Trends, Technologies and Regional Growth
30 janv. 2024 07h36 HE | Research and Markets
Dublin, Jan. 30, 2024 (GLOBE NEWSWIRE) -- The "Global 3D-Printed Organs Market 2030 by Organ, Technology, Material, Application, End-user & Region - Partner & Customer Ecosystem Competitive...
Organovo Logo (2 Color Med-Res-082117).png
Organovo Presents FXR314 3D Human Tissue Model Findings That Show Improved Epithelial Barrier Function and Fibrosis Reduction at Crohn’s and Colitis Congress
25 janv. 2024 08h05 HE | Organovo, Inc.
SAN DIEGO, Jan. 25, 2024 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (Nasdaq: ONVO), a clinical stage biotechnology company focused on developing FXR314 in inflammatory bowel disease (IBD),...
United Kingdom 3d Printing Market Number Of Private Sector Businesses By Sector United Kingdom 2022
United Kingdom 3D Printing Market: Poised for Remarkable Growth by 2028 - Driven by Technological Advances and Increased Adoption in Health and Automotive Sectors
23 janv. 2024 22h28 HE | Research and Markets
Dublin, Jan. 23, 2024 (GLOBE NEWSWIRE) -- The "United Kingdom 3D Printing Market Size & Share Analysis - Growth Trends & Forecasts (2023 - 2028)" report has been added to ...
Organovo Logo (2 Color Med-Res-082117).png
Organovo To Present FXR314 IBD 3D Model Findings at Upcoming Crohn’s and Colitis Congress
09 janv. 2024 08h05 HE | Organovo, Inc.
SAN DIEGO, Jan. 09, 2024 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (NASDAQ: ONVO), a clinical stage biotechnology company that is focused on developing FXR314 in inflammatory bowel disease (IBD),...